Stocks and Investing
Stocks and Investing
Tue, October 30, 2018
[ 12:00 AM ] - United States, WOPRAI
Mon, October 29, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Lebowitz Downgraded (SNDX) to Hold on, Oct 29th, 2018
David Lebowitz of Morgan Stanley, Downgraded "Syndax Pharmaceuticals, Inc." (SNDX) to Hold on, Oct 29th, 2018.
David has made no other calls on SNDX in the last 4 months.
There are 2 other peers that have a rating on SNDX. Out of the 2 peers that are also analyzing SNDX, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $12 on, Thursday, October 11th, 2018
- Edward White of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $30 on, Thursday, July 12th, 2018
Contributing Sources